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Measles - an old children's disease to remember
Sarampo - uma velha doença infantil a relembrar
Marta Custódio1, Tânia Strecht1, Jana Zelinová1, Anabela Marques2
ABSTRACT
Measles is a serious, highly contagious viral disease. The measles virus is a single-stranded, RNA
virus of the genus Morbillivirus within the family Paramyxoviridae, transmitted by air, through
droplets of aerosols or by direct contact with respiratory secretions of infected individuals. The
infection is acquired through the mucosa of respiratory tract or conjunctiva.
In 2005, the World Health Organization established that measles eradication in the European Region
should be achieved by 2010, but despite the measures adopted by the various countries, measles
re-emerged, with 10271 cases reported only in 2013 in 30 states of European Union, with more
than 91% of them in Germany, Italy, Netherland and United Kingdom.
In the beginning of 2017, Portugal was threatened with a measles outbreak, reporting in the first
five months of the year 31 confirmed cases, 20 (65%) of them in adults (18 or older), of which
45% (13) were in health professionals.
Because this measles outbreak had so many cases in adults, the authors decided to make a brief
review, trying to remember an old infection, not so well known by younger doctors, and that can
be overlooked in the approach of the adult patients.
The authors also point out that measles virus could virtually be eradicated as there is an effective
vaccine and there is no reservoir in nature for the virus other than humans.
Keywords: Measles. Outbreak. Vaccine, MMR. Vaccination.
RESUMO
O sarampo é uma doença viral grave e altamente contagiosa.
O vírus do sarampo é um vírus de ARN, cadeia simples, do gênero Morbillivirus, da família
Paramyxoviridae, transmitido pelas vias aéreas, através de gotículas de aerossóis ou por contato
direto com secreções respiratórias de indivíduos infectados. A infecção é adquirida pelo contato
dessas gotículas com a mucosa do trato respiratório ou conjuntiva.
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INTRODUCTION
Measles is a serious, highly contagious vi-
ral disease,1-4 remaining worldwide one of the
leading causes of death in young children.2,3
Humans are the natural hosts and until now
no animal reservoirs are known to exist,2,3 which
makes worldwide eradication of measles achiev-
able, if all the measures are taken, specially vac-
cination.2-6
In some outbreaks one of the leading cause
of measles transmission is a delay in the diagno-
sis (even after rash appearance) due to non-
awareness, unfamiliarity of measles in adults and
the difficulty in differentiating it from other febrile
diseases with rash.7 Furthermore, infected people
are usually contagious from four days before un-
til four days after rash onset,1,2,3,5,6 and there is
no fast diagnosis test permitting a rapid exclusion
of this disease.
Nosocomial transmission is believed to be
an important and emerging way of spreading the
infection,8 so trying to prevent that, the authors
make a brief review of this old infection, highlight-
ing its peculiarities, emphasizing the need to
maintain adequate vaccination coverage.
INFECTIOUS AGENT
Measles virus is a single-stranded, RNA vi-
rus of the genus Morbillivirus within the family
Paramyxoviridae.1-6
Epidemiology
It's a universal disease,3 occurring all
around the world.
Humans are the natural hosts of the virus
and until now no animal reservoirs are known to
exist,1,2,3 which makes worldwide eradication of
measles achievable if all the measures are taken,
specially vaccination.1-5,7,8,9
Since 2000, when measles was declared
eliminated from the United States of America, the
annual number of cases has ranged from a low of
37 in 2004 to a high of 667 in 2014.3 Nowadays,
six European Union/European Region (EU/ER)
countries still have endemic transmission: Belgium,
France, Germany, Italy, Poland and Romania,6 but
multiple others are facing outbreaks.
Measles is a highly contagious viral dis-
ease,1-9 mostly transmitted by direct contact;
acquired throughout the mucosa of respiratory
tract or conjunctiva, by air droplets of aerosols or
contact with respiratory secretions of infected in-
dividuals.1-6 Transmission by indirect contact with
contaminated materials is infrequent but also
possible.1 The virus can be in the environment for
up to two hours.8
It's a winter and spring disease, there is
traditionally a transmission attached to the places
where people cohabit closely, like hospitals, clin-
ics, health centres, churches, schools, among oth-
ers,1,10 mostly because in the beginning of the
illness the symptoms are mild and people, even
Em 2005, a Organização Mundial de Saúde estabeleceu que o objetivo para a erradicação do
sarampo na Região Europeia seria até 2010 mas, apesar das medidas adotadas pelos diversos
países, o sarampo ressurgiu, com 10271 casos relatados somente em 2013 em 30 estados da
União Europeia, com mais de 91% deles na Alemanha, Itália, Holanda e Reino Unido.
No início de 2017, Portugal foi ameaçado por um surto de sarampo, relatando nos primeiros cinco
meses do ano 31 casos confirmados, 20 (65%) em adultos (com idade igual ou superior a 18), dos
quais 45% (13) foram em profissionais de saúde.
Face a este surto de sarampo ter tantos casos em adultos, os autores decidiram fazer uma breve
revisão, tentando relembrar uma infeção antiga, não tão conhecida pelos médicos mais jovens e
que pode ser esquecida na abordagem de um doente adulto.
Os autores salientam igualmente que o vírus do sarampo pode virtualmente ser erradicado, pois
existe uma vacina eficaz e não existe na natureza nenhum reservatório para o vírus, além dos
humanos.
Palavras chave: Sarampo. Surtos de Doenças. Vacina SCR. Vacinação.
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feeling ill (sometimes already with fever) continue
their routines until rash appears, associated with
the fact that patients are most contagious four
days before up to four days after the appearance
of the rash.1,2,3,5,9 Immunocompromised patient or
a patient who took immunoglobulin can spread
the virus for a longer time.1-6,9
Clinical presentation (figure 1)
The incubation period (from exposure to
onset of fever) ranges from 7 to 21 days (me-
dium 10-11),1,3,6,9 known to be more prolonged in
adults.9
The prodromal period (symptomatic period
before rash) courses with fever (as high as
40.6°C), conjunctivitis, coryza (nasal congestion,
runny nose, sneezes) and cough. Koplik spots are
pathognomonic for measles, appears two days
before rash, and are characterized by being small
spots with white or bluish-white centres on an
erythematous base on the buccal mucosa, first
near premolars with possibility of generalization
to the remaining mucosa.1,2,3,6,9
Rash usually emerges about 14 days after
exposure.3 A characteristic red, maculopapular,
coalescent rash, appears on the third to seventh
day after the beginning of clinical complaints.3,5,6
(figure 2). It has a cephalocaudal distribution,
starting on the head and reaching the feet by the
third day and lasts four to seven days.1,3,5,6
After the disappearance of the rash, there
may be a thin furfuraceous scaling.
Figure 1:  Clinical presentation over time frame.
Figure 2: Rash in adult with confirmed measles.
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Contagious period is between the fourth
day before to the fourth day after rash appear-
ance.1,2,3,5,6
Generalized lymphadenomegalies is fre-
quent and more evident at the cervical and
occipital levels.1
In vaccinated patients sometimes symp-
toms reported are modified or nonclassic. They
may have less severe manifestations and/or of
shorter duration than what is typically observed
in a primary infection, not easily identified if not
fit into an outbreak or epidemiological context.11
Complications
May arise from viral replication or bacterial
superinfection and may occur during or after the
rash.1,5 The risk of serious complications and death
(1-3/1000 cases) is highest for children aged ≤ 5
years and adults aged ≥ 20 years and in patients
with poor nutritional status and immunocompro-
mised individuals.1,2,3,5
Most common complications include diar-
rhoea, middle ear infection, pneumonia (accounts
for six out of ten measles associated deaths),1,2,3
among others as laryngitis, myocarditis, pancre-
atitis and appendicitis.1
Encephalitis is rare but can result in perma-
nent brain damage.1,3,5 Subacute Sclerosing
Panencephalitis (SSPE) is also rare but fatal, gen-
erally occurs when measles is acquired earlier in
life, developing 7 to 10 years after acute infec-
tion.12,13
Measles in pregnancy results in high fetal
morbidity and mortality, miscarriages and still-
births.1,2,4,5
Diagnosis
Measles is difficult to distinguish from other
causes of febrile illnesses with rash, easily mis-
taken with rubella, parvovirus B19, human herp-
esvirus type 6 (HHV-6) and dengue.6
Classical clinical diagnostic criteria are fe-
ver with maculopapular rash and at least one of
the three - cough, rhinitis and/or conjunctivitis.
However, it's known that a few cases can sero-
convert without experiencing any symptoms.14
Laboratory confirmation is essential for the
definitive diagnosis of measles and for measures
to contain and control outbreaks or sporadic
cases, so in possible and probable cases, collec-
tion of products for detection of viral RNA by PCR
isolation should be done at the same time as the
collection for serology.7
The detection of viral RNA by PCR is more
likely to be positive when the collection is per-
formed early (best on the onset of the rash and
up to ten days later); negative results do not in-
validate the diagnosis and is mostly important to
clarify cases with inconclusive serology.7
In some countries, like Brazil, where PCR is
not easily available, the serologic diagnosis is
enough to confirm infection.
In an unvaccinated patient IgM antibodies
to measles virus usually occur in the first one to
four days of exanthema, with a peak at the end
of the first week after the appearance of the rash
and progressively decrease for six to eight weeks.
So it should be collected serology in the first
72 hours after the appearance of the rash, and
should be confirmed 72 hours later, to exclude a
false negative result.7
IgG antibodies rises usually seven to ten
days after the onset of the rash and persist
throughout life.
In cases of IgM + and IgG + antibodies in
the acute phase, a second sample, collected ten
or more days after the first, should show a sig-
nificant increase if it is case of measles.7
In cases of IgM + and IgG - antibodies in
the acute phase of the disease, a second sample,
collected ten days or more after the first, should
show elevation of IgG antibodies. If no increase
is verified, the IgM + antibody result will have been
a false positive.7
In vaccinated patients there is often a very
attenuated and transient IgM antibody response,
so IgM - does not exclude the diagnosis of
measles, being the PCR the best method for the
confirmation of these cases.7
Treatment
Treatment is supportive.1,2,3,5
WHO recommends vitamin A for all children
with acute measles, regardless of their country
of residence, to reduce the risk of complications.3,15
Bacterial superinfections are common and
should be treated with antibiotics but prophylac-
tic treatment is not indicated. Continued fever
beyond two days after the onset of rash may be
an indication of complications.6
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Prevention
Immunization is considered the most effec-
tive measure of prevention against measles.5,6,8,13
The vaccine it's a highly effective live attenuated
strain vaccine, with an excellent safety profile.16,17
Rare adverse events may occur. In adults were
register for example anaphylaxis (1-3,5 occur-
rences per million doses administer) and thromb-
ocytopenia (3-4 cases per 100000 doses).17 Until
now no evidence supported an association be-
tween vaccination with hearing loss, retinopathy,
optic neuritis, Guillain-Barré Syndrome, type 1 Dia-
betes, Crohn's disease or autism.16
Vaccination against measles was introduced
in the Portugal National Vaccination Plan in 1974,
but in 1987 it was changed to trivalent vaccine
against measles, mumps and rubella (MMR). By
1990 a second dose was introduced to overcome
the 5-15% failure of the vaccines at the initial
dose.2,3,5 At this time MMR is administered at 12
months and the second dose at five-six years of
age.5,6
An anti-vaccination movement is a problem
emerging all around the world. This and imported
cases of measles bring a new obstacle to eradi-
cation.
There are outbreaks even between vacci-
nated populations, being the number of doses of
vaccine received, the most important predictor of
antibody response.14 Because of that, all health
professionals should have two doses (The sec-
ond dose of the vaccine should be administer at
least 28 days apart).
After vaccination people can not transmit
measles.16
People who have had measles are consid-
ered to be protected for life, not requiring vacci-
nation,5,14,18 but there is the possibility of misdi-
agnosing this infection with another exanthematic
disease. To avoid unnecessary risks in Brazil, all
health professionals should be vaccinated regard-
less history of previous infection.
Post-exposure prophylaxis can be done
with vaccine (if administered within 72 hours of
initial measles exposure) or with immunoglobulin
(if administered within six days of exposure) and
may provide some protection or modify the clini-
cal course of disease.1,3,5,6
Patients should be isolated, excluding them
from community setting (school, hospital,
childcare; place of work) until the fourth day after
the beginning of the rash.1,3,6
Healthcare personnel without evidence of
immunity should be excused from duty from day
five after first exposure to day 21 after last expo-
sure, regardless of post-exposure vaccine.3,11
CONCLUSION
Measles is an acute, highly contagious dis-
ease seen all around the world, at any age and
that can be fatal.
Worldwide eradication of measles is theo-
retical possible because humans are the only vi-
rus natural host and a secure vaccine is available.
Vaccination is considered the best way to
protect yourself and others against measles, re-
gardless of the age and despite a known vaccine
failure.
Recalling this old disease between the
health professionals is crucial, aiming for an early
identification, preventing transmission and even
avoiding progression to an outbreak.
In Portugal measles is an obligatory notifi-
cation disease done in National System of Epide-
miological Surveillance online platform,5 being that
a tool for health authorities to early identify spo-
radic cases or outbreaks.
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